TIXiMED is a biotechnology company that develops and commercialises medicines for diabetes treatment.
TIXiMED has raised $2.6M in total funding. The most recent round was Debt Financing. The last funding was announced in December 2024.
TIXiMED's investors include The Leona M. and Harry B. Helmsley Charitable Trust.
TIXiMED is headquartered in Birmingham, United States.
TIXiMED is a biotechnology company that develops and commercialises medicines for diabetes treatment.
TIXiMED is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TIXiMED — Funding & Investors." VCBacked, December 19, 2024, https://www.vcbacked.co/company/tiximed. Accessed November 12, 2026.
VCBacked. (2024). TIXiMED — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/tiximed
{{cite web |title=TIXiMED — Funding & Investors |url=https://www.vcbacked.co/company/tiximed |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at TIXiMED? Request a listing update